company background image
RENE

ReNeuron GroupAIM:RENE Stock Report

Market Cap

UK£54.2m

7D

-6.9%

1Y

17.3%

Updated

30 Nov, 2021

Data

Company Financials +
RENE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

RENE Stock Overview

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom.

ReNeuron Group Competitors

SanBio

TSE:4592

JP¥53.5b

Lineage Cell Therapeutics

NYSEAM:LCTX

US$337.1m

International Stem Cell

OTCPK:ISCO

US$4.0m

Price History & Performance

Summary of all time highs, changes and price drops for ReNeuron Group
Historical stock prices
Current Share PriceUK£0.95
52 Week HighUK£1.54
52 Week LowUK£0.70
Beta0.68
1 Month Change-15.56%
3 Month Change-8.21%
1 Year Change17.28%
3 Year Change68.14%
5 Year Change-66.96%
Change since IPO-96.35%

Recent News & Updates

Oct 12
Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Jun 04
Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

RENEGB BiotechsGB Market
7D-6.9%-2.4%-2.6%
1Y17.3%22.5%10.9%

Return vs Industry: RENE underperformed the UK Biotechs industry which returned 24.4% over the past year.

Return vs Market: RENE exceeded the UK Market which returned 13.8% over the past year.

Price Volatility

Is RENE's price volatile compared to industry and market?
RENE volatility
RENE Average Weekly Movement7.9%
Biotechs Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: RENE is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: RENE's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
199738Olav Hellebohttps://www.reneuron.com

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells.

ReNeuron Group Fundamentals Summary

How do ReNeuron Group's earnings and revenue compare to its market cap?
RENE fundamental statistics
Market CapUK£54.21m
Earnings (TTM)-UK£11.35m
Revenue (TTM)UK£257.00k

211.1x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RENE income statement (TTM)
RevenueUK£257.00k
Cost of RevenueUK£9.50m
Gross Profit-UK£9.25m
ExpensesUK£2.10m
Earnings-UK£11.35m

Last Reported Earnings

Mar 31, 2021

Next Earnings Date

Nov 30, 2021

Earnings per share (EPS)-0.20
Gross Margin-3,597.67%
Net Profit Margin-4,415.18%
Debt/Equity Ratio0%

How did RENE perform over the long term?

See historical performance and comparison

Valuation

Is ReNeuron Group undervalued compared to its fair value and its price relative to the market?

2.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RENE's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RENE's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RENE is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.

PE vs Market: RENE is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RENE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RENE is good value based on its PB Ratio (2.9x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is ReNeuron Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

17.1%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RENE's forecast earnings growth is above the savings rate (0.9%).

Earnings vs Market: Insufficient data to determine if RENE's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RENE's revenue (17.1% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: RENE's revenue (17.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RENE's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ReNeuron Group performed over the past 5 years?

3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RENE is currently unprofitable.

Growing Profit Margin: RENE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RENE is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare RENE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: RENE has a negative Return on Equity (-60.02%), as it is currently unprofitable.


Financial Health

How is ReNeuron Group's financial position?


Financial Position Analysis

Short Term Liabilities: RENE's short term assets (£24.5M) exceed its short term liabilities (£5.9M).

Long Term Liabilities: RENE's short term assets (£24.5M) exceed its long term liabilities (£562.0K).


Debt to Equity History and Analysis

Debt Level: RENE is debt free.

Reducing Debt: RENE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RENE has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: RENE has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 0% each year.


Dividend

What is ReNeuron Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RENE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RENE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RENE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RENE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RENE's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Olav Hellebo (56 yo)

7.17yrs

Tenure

UK£488,000

Compensation

Mr. Olav Hellebo, MBA, BBA, has been the Chief Executive Officer of ReNeuron Group plc since September 8, 2014. Mr. Hellebo served as an Executive of Aqualis ASA. He is a Co-Founder and Chairman of Palma B...


CEO Compensation Analysis

Compensation vs Market: Olav's total compensation ($USD646.14K) is above average for companies of similar size in the UK market ($USD324.53K).

Compensation vs Earnings: Olav's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: RENE's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: RENE's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RENE insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79%.


Top Shareholders

Company Information

ReNeuron Group plc's employee growth, exchange listings and data sources


Key Information

  • Name: ReNeuron Group plc
  • Ticker: RENE
  • Exchange: AIM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£54.210m
  • Shares outstanding: 57.06m
  • Website: https://www.reneuron.com

Number of Employees


Location

  • ReNeuron Group plc
  • Pencoed Business Park
  • Pencoed
  • Mid Glamorgan
  • CF35 5HY
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 21:33
End of Day Share Price2021/11/30 00:00
Earnings2021/03/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.